Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1948 2
1954 3
1955 2
1956 1
1959 2
1960 5
1961 4
1962 1
1963 1
1965 3
1966 2
1967 4
1969 4
1970 5
1971 1
1972 1
1974 1
1975 1
1976 6
1977 2
1978 2
1979 2
1980 1
1981 5
1982 1
1983 2
1984 1
1985 5
1986 1
1987 1
1988 3
1989 1
1990 4
1991 6
1992 9
1993 6
1994 3
1995 3
1996 9
1997 5
1998 3
1999 9
2000 9
2001 2
2002 9
2003 3
2004 4
2005 10
2006 14
2007 12
2008 17
2009 19
2010 17
2011 16
2012 28
2013 19
2014 26
2015 45
2016 29
2017 45
2018 44
2019 56
2020 59
2021 57
2022 55
2023 52
2024 21

Text availability

Article attribute

Article type

Publication date

Search Results

730 results

Results by year

Filters applied: . Clear all
Page 1
Efficacy of maintenance olaparib plus bevacizumab according to clinical risk in patients with newly diagnosed, advanced ovarian cancer in the phase III PAOLA-1/ENGOT-ov25 trial.
Harter P, Mouret-Reynier MA, Pignata S, Cropet C, González-Martín A, Bogner G, Fujiwara K, Vergote I, Colombo N, Nøttrup TJ, Floquet A, El-Balat A, Scambia G, Guerra Alia EM, Fabbro M, Schmalfeldt B, Hardy-Bessard AC, Runnebaum I, Pujade-Lauraine E, Ray-Coquard I. Harter P, et al. Gynecol Oncol. 2022 Feb;164(2):254-264. doi: 10.1016/j.ygyno.2021.12.016. Epub 2021 Dec 22. Gynecol Oncol. 2022. PMID: 34952708 Free article. Clinical Trial.
OBJECTIVES: Adding maintenance olaparib to bevacizumab provided a significant progression-free survival (PFS) benefit in patients with newly diagnosed, advanced ovarian cancer in the randomized, double-blind PAOLA-1/ENGOT-ov25 trial (NCT02477644). We analyzed PFS by clinic …
OBJECTIVES: Adding maintenance olaparib to bevacizumab provided a significant progression-free survival (PFS) benefit in patients with newly …
Homologous Recombination Repair Gene Mutations to Predict Olaparib Plus Bevacizumab Efficacy in the First-Line Ovarian Cancer PAOLA-1/ENGOT-ov25 Trial.
Pujade-Lauraine E, Brown J, Barnicle A, Wessen J, Lao-Sirieix P, Criscione SW, du Bois A, Lorusso D, Romero I, Petru E, Yoshida H, Vergote I, Colombo N, Hietanen S, Provansal M, Schmalfeldt B, Pignata S, Martín Lorente C, Berton D, Runnebaum IB, Ray-Coquard I. Pujade-Lauraine E, et al. JCO Precis Oncol. 2023 Jan;7:e2200258. doi: 10.1200/PO.22.00258. JCO Precis Oncol. 2023. PMID: 36716415 Free PMC article. Clinical Trial.
PURPOSE: The PAOLA-1/ENGOT-ov25 trial of maintenance olaparib plus bevacizumab for newly diagnosed advanced high-grade ovarian cancer demonstrated a significant progression-free survival (PFS) benefit over placebo plus bevacizumab, particularly in patients with homologous …
PURPOSE: The PAOLA-1/ENGOT-ov25 trial of maintenance olaparib plus bevacizumab for newly diagnosed advanced high-grade ovarian cancer …
Maintenance olaparib plus bevacizumab in patients with newly diagnosed advanced high-grade ovarian cancer: Main analysis of second progression-free survival in the phase III PAOLA-1/ENGOT-ov25 trial.
González-Martín A, Desauw C, Heitz F, Cropet C, Gargiulo P, Berger R, Ochi H, Vergote I, Colombo N, Mirza MR, Tazi Y, Canzler U, Zamagni C, Guerra-Alia EM, Levaché CB, Marmé F, Bazan F, de Gregorio N, Dohollou N, Fasching PA, Scambia G, Rubio-Pérez MJ, Milenkova T, Costan C, Pautier P, Ray-Coquard I; PAOLA1/ENGOT-ov25 investigators. González-Martín A, et al. Eur J Cancer. 2022 Oct;174:221-231. doi: 10.1016/j.ejca.2022.07.022. Epub 2022 Sep 5. Eur J Cancer. 2022. PMID: 36067615 Free article. Clinical Trial.
BACKGROUND: PAOLA-1/ENGOT-ov25 (NCT02477644) demonstrated a significant progression-free survival (PFS) benefit with maintenance olaparib plus bevacizumab versus placebo plus bevacizumab in newly diagnosed, advanced ovarian cancer. We report the prespecified main second pr …
BACKGROUND: PAOLA-1/ENGOT-ov25 (NCT02477644) demonstrated a significant progression-free survival (PFS) benefit with maintenance olap …
The SIFIPAC/WSES/SICG/SIMEU guidelines for diagnosis and treatment of acute appendicitis in the elderly (2019 edition).
Fugazzola P, Ceresoli M, Agnoletti V, Agresta F, Amato B, Carcoforo P, Catena F, Chiara O, Chiarugi M, Cobianchi L, Coccolini F, De Troia A, Di Saverio S, Fabbri A, Feo C, Gabrielli F, Gurrado A, Guttadauro A, Leone L, Marrelli D, Petruzzelli L, Portolani N, Prete FP, Puzziello A, Sartelli M, Soliani G, Testini M, Tolone S, Tomasoni M, Tugnoli G, Viale P, Zese M, Ishay OB, Kluger Y, Kirkpatrick A, Ansaloni L. Fugazzola P, et al. World J Emerg Surg. 2020 Mar 10;15(1):19. doi: 10.1186/s13017-020-00298-0. World J Emerg Surg. 2020. PMID: 32156296 Free PMC article. Review.
The aim of the present work was to investigate age-related factors that could influence a different approach, compared to the 2016 WSES Jerusalem guidelines on general population, in terms of diagnosis and management of elderly patient with acute appendicitis. During the XXIX Nat …
The aim of the present work was to investigate age-related factors that could influence a different approach, compared to the 2016 WSES Jeru …
PARP inhibitor predictive value of the Leuven HRD test compared with Myriad MyChoice CDx PLUS HRD on 468 ovarian cancer patients from the PAOLA-1/ENGOT-ov25 trial.
Loverix L, Vergote I, Busschaert P, Vanderstichele A, Venken T, Boeckx B, Harter P, Brems H, Van Nieuwenhuysen E, Pignata S, Baert T, Gonzalez-Martin A, Han S, Marth C, Neven P, Colombo N, Berteloot P, Mäenpää J, Olbrecht S, Laga T, Sablon E, Ray-Coquard I, Pujade-Lauraine E, Lambrechts D, Van Gorp T. Loverix L, et al. Eur J Cancer. 2023 Jul;188:131-139. doi: 10.1016/j.ejca.2023.04.020. Epub 2023 Apr 27. Eur J Cancer. 2023. PMID: 37245441
BACKGROUND: The PAOLA-1/ENGOT-ov25 trial showed improved progression-free (PFS) and overall survival (OS) in homologous recombination deficient (HRD) positive patients treated with olaparib, but not when HRD negative (HRD tested with MyChoice CDx PLUS [Myriad test]). ...We …
BACKGROUND: The PAOLA-1/ENGOT-ov25 trial showed improved progression-free (PFS) and overall survival (OS) in homologous recombination …
Italian COnsensus in Neuroradiological Anesthesia (ICONA).
Castioni CA, Amadori A, Bilotta F, Bolzon M, Barboni E, Caricato A, Dall'acqua G, DI Paola F, Forastieri Molinari A, Gritti P, LA Rosa I, Longo M, Maglione C, Martorano P, Munari M, Perotti V, Rasulo F, Ruggiero M, Santoro A, Scudeller L, Tumolo M, Mazzeo AT; SIAARTI Study Group on Neuroanesthesia and Neuroresuscitation, AINR, SARNePI, SINCh. Castioni CA, et al. Minerva Anestesiol. 2017 Sep;83(9):956-971. doi: 10.23736/S0375-9393.17.11753-0. Epub 2017 May 11. Minerva Anestesiol. 2017. PMID: 28492296 Free article.
A multidisciplinary group including neuro- and pediatric anesthesiologists, interventional neuroradiologists, neurosurgeons, and a clinical methodologist contributed to this document. This consensus working group from 21 Italian institutions identified open questions regar …
A multidisciplinary group including neuro- and pediatric anesthesiologists, interventional neuroradiologists, neurosurgeons, and a clinical …
The Italian multiple sclerosis register.
Trojano M, Bergamaschi R, Amato MP, Comi G, Ghezzi A, Lepore V, Marrosu MG, Mosconi P, Patti F, Ponzio M, Zaratin P, Battaglia MA; Italian Multiple Sclerosis Register Centers Group. Trojano M, et al. Neurol Sci. 2019 Jan;40(1):155-165. doi: 10.1007/s10072-018-3610-0. Epub 2018 Nov 13. Neurol Sci. 2019. PMID: 30426289 Free PMC article.
Moreover, patients, physicians, industry, and policy makers have an active interest in real-world observational studies based on register data, as they have the potential to answer the questions that are most relevant to daily treatment decision-making. In 2014, the Italian …
Moreover, patients, physicians, industry, and policy makers have an active interest in real-world observational studies based on register da …
Clinical Practice Guidelines for the Nursing Management of Percutaneous Endoscopic Gastrostomy and Jejunostomy (PEG/PEJ) in Adult Patients: An Executive Summary.
Roveron G, Antonini M, Barbierato M, Calandrino V, Canese G, Chiurazzi LF, Coniglio G, Gentini G, Marchetti M, Minucci A, Nembrini L, Neri V, Trovato P, Ferrara F. Roveron G, et al. J Wound Ostomy Continence Nurs. 2018 Jul/Aug;45(4):326-334. doi: 10.1097/WON.0000000000000442. J Wound Ostomy Continence Nurs. 2018. PMID: 29994859
This article summarizes guidelines developed for nursing management of percutaneous endoscopic gastrostomy or jejunostomy (PEG/PEJ) and gastrojejunostomy (PEGJ) tubes, developed by the Italian Association of Stoma care Nurses (AIOSS-Associazione Italiana Operatori Sanitari …
This article summarizes guidelines developed for nursing management of percutaneous endoscopic gastrostomy or jejunostomy (PEG/PEJ) and gast …
The new Italian registry of infantile thrombosis (RITI): A reflection on its journey, challenges and pitfalls.
Pelizza MF, Martinato M, Rosati A, Nosadini M, Saracco P, Giordano P, Luciani M, Ilardi L, Lasagni D, Molinari AC, Bagna R, Palmieri A, Ramenghi LA, Grassi M, Magarotto M, Magnetti F, Francavilla A, Indolfi G, Suppiej A, Gentilomo C, Restelli R, Tufano A, Tormene D, Pin JN, Tona C, Meneghesso D, Rota L, Conti M, Russo G, Lorenzoni G, Gregori D, Sartori S, Simioni P; Collaborators of the R.I.T.I. (Italian Registry of Infantile Thrombosis). Pelizza MF, et al. Front Pediatr. 2023 Apr 20;11:1094246. doi: 10.3389/fped.2023.1094246. eCollection 2023. Front Pediatr. 2023. PMID: 37152311 Free PMC article.
Quality evidence is limited in this field, and registry studies provide an essential base for research. The aim of this paper is to present the new Italian Registry of Infantile Thrombosis (RITI), set it into the scene of international thrombosis and stroke registries, and …
Quality evidence is limited in this field, and registry studies provide an essential base for research. The aim of this paper is to present …
730 results